FDA grants Priority Review to atezolizumab as first-line monotherapy for advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without EGFR or ALK mutations with high PD-L1 expression

Submission to FDA is based on results from phase III IMpower110 study, which showed atezolizumab monotherapy improved overall survival (OS) by 7.1 months compared with chemotherapy (median OS=20.2 vs.13.1 months; HR 0.595, 95% CI: 0.398–0.890; p=0.0106)


Biospace Inc.